<DOC>
	<DOCNO>NCT02721979</DOCNO>
	<brief_summary>This phase II trial study well ARN-509 ( androgen receptor antagonist ARN-509 ) work treat patient prostate cancer active surveillance . Testosterone cause growth prostate cancer cell . Hormone therapy use androgen receptor antagonist ARN-509 may fight prostate cancer block use testosterone tumor cell .</brief_summary>
	<brief_title>ARN-509 Treating Patients With Prostate Cancer Who Are Active Surveillance</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine negative repeat biopsy rate site direct systematic prostate biopsy 90-days ARN-509 . SECONDARY OBJECTIVES : I . Determine rate exit 2 year active surveillance due pathologic reclassification . II . Determine overall rate exit 2 year active surveillance . III . Determine rate local treatment ( e.g . radical prostatectomy , radiation therapy , brachytherapy ) 2 year local treatment free survival . IV . Determine prostate-specific antigen ( PSA ) progression rate PSA progression free survival ( PFS ) , defined Prostate Cancer Working Group 2 ( PCWG2 ) criterion . V. Determine rate radiographic disappearance magnetic resonance imaging ( MRI ) detectable prostate cancer follow treatment ( patient baseline nodule Prostate Imaging Reporting Data System [ PIRADS ] 3 &gt; 5mm ) . VI . Investigate safety ARN-509 men undergo active surveillance ; safety evaluate incidence , severity , duration , causality , seriousness , type ( ) adverse event assess revise National Cancer Institute Common Toxicity Criteria ( NCI CTC ) , version 4.03 publish 14 June 2010 . VII . Track quality life utilize Functional Assessment Cancer Therapy-Prostate ( FACT-P ) Short Form ( SF ) 36 survey cohort . VIII . Exploratory biomarker assessment . OUTLINE : Patients receive ARN-509 orally ( PO ) daily ( QD ) 90 day . After completion study treatment , patient follow 180 , 365 , 545 , 730 day .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Receptor Antagonists</mesh_term>
	<criteria>Have sign inform consent document indicate subject understand purpose procedure require study willing participate study Be willing/able adhere prohibition restriction specify protocol Written Authorization Use Release Health Research Study Information obtain Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Histologically confirm adenocarcinoma prostate document minimum 12 core prostate biopsy complete within 1year enrollment ( note : recent prostate biopsy must demonstrate prostatic adenocarcinoma ) Favorable risk prostate cancer define : Very lowrisk : Clinical stage T1c disease PSA density ( PSAD ) &lt; 0.15 ng/mL Gleason score 6 = &lt; core biopsy = &lt; 50 % involvement biopsy core cancer , unilateral disease = &lt; 2 core biopsy percentage involvement OR Low risk : Clinical stage = &lt; T2a PSA &lt; 10 ng/mL Gleason score 6 OR Lowintermediate risk : Clinical stage T1c PSA &lt; 10 ng/ml Gleason 3+4 present = &lt; 50 % one core/site detect systematic biopsy MRI/transrectal ultrasound ( TRUS ) fusion biopsy target Gleason 6 disease cores/sites ( maximum 2 core = &lt; 50 % involvement core , unilateral disease , percentage involvement ) Willing qualify active surveillance Johns Hopkins University Washington Serum testosterone &gt; = 150 ng/dL Able swallow study drug whole tablet Hemoglobin &gt; = 9.0 g/dL , independent transfusion and/or growth factor within 3 month prior randomization Platelet count &gt; = 100,000 x 10^9/uL independent transfusion and/or growth factor within 3 month prior randomization Serum albumin &gt; = 3.0 g/dL Glomerular filtration rate ( GFR ) &gt; = 45 mL/min Serum potassium &gt; = 3.5 mmol/L Serum total bilirubin = &lt; 1.5 × upper limit normal ( ULN ) ( note : subject Gilbert 's syndrome , total bilirubin &gt; 1.5 × ULN , measure direct indirect bilirubin direct bilirubin = &lt; 1.5 × ULN , subject may eligible ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 × ULN Medications know low seizure threshold must discontinue substitute least 4 week prior study entry Agrees use condom ( even men vasectomy ) another effective method birth control sex woman childbearing potential agrees use condom sex woman pregnant study drug 3 month follow last dose study drug ; must also agree donate sperm study 3 month receive last dose study drug Prior local therapy treat prostate cancer ( e.g . radical prostatectomy , radiation therapy , brachytherapy ) Prior use ARN509 Have know allergy , hypersensitivity , intolerance ARN509 excipients Prior ongoing systemic therapy prostate cancer include , limited : Hormonal therapy ( e.g . leuprolide , goserelin , triptorelin ) Cytochrome P450 ( CYP ) 17 inhibitor ( e.g . abiraterone , ketoconazole ) Antiandrogens ( e.g . bicalutamide , nilutamide ) Second generation antiandrogens ( e.g . enzalutamide ) Immunotherapy ( e.g . sipuleucelT , ipilimumab ) Chemotherapy ( e.g . docetaxel , cabazitaxel ) Have condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement History follow : Seizure know condition may predispose seizure ( include limit prior stroke , transient ischemic attack , loss consciousness within 1 year prior randomization , brain arteriovenous malformation ; intracranial mass schwannomas meningiomas cause edema mass effect ) Severe unstable angina , myocardial infarction , symptomatic congestive heart failure , arterial venous thromboembolic event ( e.g. , pulmonary embolism , cerebrovascular accident include transient ischemic attack ) , clinically significant ventricular arrhythmia within 6 month prior randomization Any condition opinion investigator , would preclude participation study Current evidence following : Uncontrolled hypertension Gastrointestinal disorder affect absorption Active infection ( e.g . human immunodeficiency virus [ HIV ] viral hepatitis ) medical condition would make prednisone/prednisolone ( corticosteroid ) use contraindicate Any condition opinion investigator , would preclude participation study The use drug know low seizure threshold , include : atypical antipsychotic ( e.g . clozapine , olanzapine , risperidone , ziprasidone ) , bupropion , lithium , meperedine , pethidine , phenothiazine antipsychotic ( e.g . chlorpromazine , mesoridazine , thioridazine ) , tricyclic antidepressant ( e.g . amitriptyline , desipramine , doxepin , imipramine , maprotiline , mirtazapine ) The use strong cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor , include : itraconazole , clarithromycin , erythromycin , diltiazem , verapamil , delavirdine , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole , grapefruit juice ( grapefruit ) Strong CYP3A4 inducer , include : phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , efavirenz , tipranivir , St. John 's wort Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>